Edward A. Fon

Professor

Montreal Neurological Institute and Hospital
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Mitochondrial dysfunction is a hallmark of aging and a key contributor to age-related diseases including cardiovascular disease. However, molecular pathways that safeguard mitochondrial homeostasis in the aging heart remain poorly understood. Here, we identify MTFR1L as a regulator of mitophagy that binds p-S65-Ub, a key signal amplifying the PINK1/Parkin axis. We find that MTFR1L is enriched in metabolically active tissues, particularly in the heart, where it regulates Parkin signaling. Genetic deletion of Mtfr1l in mice impairs stress-induced mitophagy and Parkin activation, leading to accumulation of damaged mitochondria, increased inflammation and senescence, and accelerated age-related cardiac dysfunction. Strikingly, cardiac expression of MTFR1L progressively decreases along with aging in mice, primates, and humans, coinciding with cardiomyocyte senescence and lipofuscin accumulation. Together, these findings uncover a role for MTFR1L in regulation of the p-S65-Ub/Parkin mitophagy axis and maintenance of mitochondrial homeostasis during cardiac aging and suggest that age-associated loss of MTFR1L may contribute to age-related cardiac dysfunction. Based on these findings, we propose a therapeutic paradigm for the prevention of heart aging by restoring MTFR1L function.

Year:

2026

A classical pathological hallmark of many neurodegenerative diseases is the formation of protein-rich aggregates and inclusions. In Parkinson’s disease (PD), α-synuclein (α-syn) constitutes a major protein component of pathological inclusions, termed Lewy bodies. These α-syn aggregates are hypothesized to spread throughout the nervous system by cell-to-cell transmission acting as templates to amplify aggregate formation. In vitro generated α-syn aggregates, commonly called preformed fibrils (PFFs), have been used to investigate a number of aspects related to α-syn mediated pathology across different model systems. Here we describe a semi-automated assay to screen for small molecules that interfere with the cellular uptake and accumulation of PFFs. The assay uses dopaminergic progenitor cells (DPCs), derived from human induced pluripotent stem cells (hiPSCs). In an initial screen, we tested 1520 small molecules and identified several molecules that strongly reduce intracellular PFF load in DPCs. From these hits, candidate compounds were validated in dopaminergic neurons (DNs) to demonstrate the utility of the assay. This assay provides a robust, scalable and adaptable tool to screen for molecules that affect PFF uptake in hiPSC-derived cell models. Within the scope of this screen, it led to the identification of a set of compounds with diverse annotated targets that effectively reduce the uptake of synuclein aggregates in DPCs and DNs.

Year:

2025

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by alpha-synuclein (α-syn) aggregates termed Lewy bodies. To model PD pathology in vitro , preformed fibrils of α-syn (PFFs), which can be taken up by cells, provide a seed that drives misfolding and aggregation of endogenous α-syn, with new aggregates amplifying this process. External application of PFFs to dopaminergic neurons (DNs) increases aggregate formation, marked by α-syn phosphorylation at serine 129 (pS129-syn), a pathological PD marker. Building on this, we developed an automated synuclein seeding assay to quantify new α-syn aggregates in iPSC-derived DNs. Using pS129-syn as a readout, we show that PFFs elicit a time- and dose-dependent increase in pS129-syn aggregates. Our high-throughput assay further revealed that aggregate formation depends on endogenous α-syn levels. Treatment with PFFs produced a greater increase in pS129-syn aggregates in iPSC DNs derived from a PD patient with a triplication in the SNCA gene, which encodes the α-syn protein and which elevates total α-syn levels, relative to DNs from an isogenic iPSC line from the same individual, in which the SNCA gene mutation had been corrected by CRISPR/Cas9. In contrast, no pS129-syn signal was detected in neurons in which all copies of the SNCA gene had been knocked out (KO). This high-content imaging assay for synuclein seeding offers a platform for assessing compounds and therapeutics that may impede α-syn aggregate formation.

Year:

2025

The α-synuclein protein, encoded by SNCA gene, is a major constituent of pathological intracellular inclusions such as Lewy bodies found in the brains of patients with Parkinson’s disease and other synucleinopathies. Whereas α-synuclein phosphorylation has been much studied, comparatively less work has been devoted to other post-translational modifications such as acetylation, especially given that N-terminally acetylated α-synuclein is the most abundant endogenous form of the protein in the brain. In this study, using multiple in vitro and in vivo models, we sought to better understand the role of N-terminal acetylation in the pathogenesis of synucleinopathies. We found that N-terminal acetylation slowed aggregation of both α-synuclein monomers and pre-formed fibrils in vitro . Uptake of acetylated α-synuclein pre-formed fibrils into both immortalized cell lines and iPSC-derived dopamine neurons was also slowed compared non-acetylated fibrils. In addition, exposure to acetylated pre-formed fibrils induced less seeding of endogenous α-synuclein, as measured by the accumulation of Serine129-phosphorylated α-synuclein inclusions in both iPSC-derived dopamine neurons and mouse brain. Finally, mice injected with N-terminally acetylated α-synuclein pre-formed fibrils survived significantly longer than mice injected with non-acetylated fibrils. Taken together, our study indicates that N-terminal acetylation reduces α-synuclein aggregation, uptake into cells, seeding of endogenous α-synuclein, and toxicity in vivo , suggesting that this prevalent post-translational modification represents a potent, physiologically relevant protective mechanism, which has thus far largely not been taken into consideration in most experimental paradigms of Parkinson’s disease and synucleinopathies.

Year:

2025

Variants in the LRRK2 and GBA1 genes are among the most common risk factors associated with Parkinson’s disease (PD). Both patients carrying PD-associated variants in GBA1 , encoding lysosomal enzyme glucocerebrosidase (GCase), and a subset of non-carrier patients have been shown to have reduced GCase enzymatic activity, suggesting that reduced GCase activity may be a feature of both genetic and a subset of sporadic PD. However, the effect of PD-associated variants in LRRK2 , encoding a serine/threonine kinase, on GCase activity remains controversial, with conflicting results in various tissues and cell types. Moreover, rare patients carrying both GBA1 and LRRK2 risk alleles seem to have a more benign disease course than carriers of GBA1 variants alone, suggesting a complex interplay between these two genes in PD. Here we evaluate the effect of LRRK2 kinase activity on GCase activity in human induced pluripotent stem cell (iPSC)-derived microglia (iMGs), a PD-relevant brain cell type expressing high levels of LRRK2. Using CRISPR editing, isogenic control iPSC lines were generated to match PD patient-derived iPSC lines harbouring the LRRK2 p.G2019S, p.M1646T, or p.N551K-p.R1398H protective haplotype variants. Whereas iMGs harbouring the p.M1646T variant, and the protective haplotype, respectively increased and decreased phosphorylation of canonical LRRK2 substrate, Rab10, GCase protein levels and activity were not altered in any of the LRRK2 variant lines. Additionally, whereas pharmacological inhibition of LRRK2 kinase activity had no impact on GCase activity in iMGs under basal conditions, it attenuated the increase in GCase activity elicited in response to interferon γ (IFNγ) treatment. Moreover, GCase activity induced by IFNγ was reduced in PD risk LRRK2 p.M1646T iMGs and increased in p.N551K-p.R1398H protective haplotype iMGs compared to their isogenic corrected controls, congruent with their respective effects on LRRK2 kinase activity and PD risk. Thus, our data suggests a role for LRRK2 kinase activity in regulation of GCase activity in response to neuroinflammation.

Year:

2025

Genetic studies have identified hundreds of risk genes for neurodegenerative diseases, yet translating these variants into disease mechanisms remains limited by incomplete knowledge of the protein products. Here, we present the ALS-Reproducible Antibody Platform (ALS-RAP), a systematic effort to characterize 303 antibodies targeting 33 amyotrophic lateral sclerosis (ALS) risk genes: ACSL5, ALS2, ANG, ANXA11, ATXN2, C9orf72, CAV1, CCNF, CHCHD10, CHMP2B, FIG4, FUS, HNRNPA1, HNRNPA2B1, KIF5A, LGALS1, MATR3, NEK1, OPTN, PFN1, SETX, SIGMAR1, SOD1, SPG11, SQSTM1, TAF15, TARDBP, TBK1, TIA1, TUBA4A, UBQLN2, VAPB, and VCP using knockout-based characterization to identify high-quality reagents in common applications. Using these antibodies, we profiled protein expression across human iPSC-derived and primary neurological cell types. Protein-level analyses revealed diverse cell type-specific expression patterns, with subsets of ALS-associated proteins enriched in glial or neuronal populations. This work provides a validated antibody toolbox and ALS protein resource for translating genetic risk into mechanistic insights.

Year:

2025

In Parkinson’s disease and other synucleinopathies, α-synuclein (α-Syn) misfolds and forms Ser 129 -phosphorylated aggregates (pSyn 129 ). The factors controlling this process are largely unknown. Here, we used arrayed CRISPR-mediated gene activation and ablation to discover new pSyn 129 modulators. Using quadruple-guide RNAs (qgRNAs) and Cas9, or an inactive Cas9 version fused to a synthetic transactivator, we ablated 2304 and activated 2428 human genes related to mitochondrial, trafficking and motility function in HEK293 cells. After exposure of cells to α-Syn fibrils, pSyn 129 signals were recorded by high-throughput fluorescence microscopy and aggregates were identified by image analysis. We found that pSyn 129 was increased by activating the mitochondrial protein OXR1, which decreased ATP levels and altered the mitochondrial membrane potential. Instead, pSyn 129 was reduced by ablation of the endoplasmic reticulum (ER)-associated protein EMC4, which enhanced ER-driven autophagic flux and lysosomal clearance. OXR1 activation preferentially modulated cellular reactions to fibrils derived from multiple system atrophy (MSA) patients, whereas EMC4 ablation broadly reduced pSyn 129 across diverse α-Syn polymorphs. These findings were confirmed in human iPSC-derived cortical and dopaminergic neurons, where OXR1 preferentially promoted somatic aggregation and EMC4 reduced both somatic and neuritic aggregates. These results uncover previously unrecognized roles for OXR1 and EMC4 in α-Syn aggregation, thereby broadening our mechanistic understanding of synucleinopathies.

Year:

2025

α-Synuclein seed amplification assays are a promising diagnostic tool for synucleinopathies such as Parkinson’s disease and multiple system atrophy. Standardized conditions are required to ensure a high degree of inter- and intra-laboratory reproducibility when performing these assays. A significant issue that hinders the utility of seed amplification assays is the de novo aggregation propensity of the α-synuclein substrate as well as inter-batch heterogeneity. While much work has focused on determining appropriate seed amplification assay buffer compositions as well as the type and amount of seed used, a robust comparison of α-synuclein substrate purification methods has not been reported. We therefore compared the utility of recombinant α-synuclein purified using four different methods as seed amplification assay substrates across two laboratories. Osmotic shock-purified α-synuclein monomer substrate showed the lowest propensity for de novo aggregation, which translated into being the best substrate for seed amplification assay reactions seeded with α-synuclein preformed fibrils or patient brain homogenates. Furthermore, osmotic shock α-synuclein monomer showed the best inter-batch reproducibility compared to all other substrates tested. As α-synuclein seed amplification assays continue to evolve and move towards adoption in the clinical realm, this work showcases the vital importance of standardizing the production and characterization of recombinant α-synuclein substrate. We encourage the widespread adoption of osmotic shock α-synuclein monomer as the universal substrate for seed amplification assays to maximize intra- and inter-laboratory reproducibility.

Year:

2025

Human midbrain organoids (hMOs) show promise as a patient-derived model for the study of Parkinson's disease (PD). Yet, much remains unknown about how accurately hMOs recapitulate key features of PD in the human brain. In both PD patients and animal models, disease progression leads to characteristic changes in neural activity throughout the basal ganglia. Here we demonstrate that patient-derived induced pluripotent stem cell (iPSC) hMOs harboring a triplication in the SNCA gene, encoding α-synuclein, a key protein in PD pathogenesis, can recapitulate PD-associated changes in neural activity. Namely, we observe hyperactive network activity in SNCA triplication hMOs, but not in isogenic, CRISPR-corrected iPSC hMOs. These changes are characterized by an increase in the number of bursts and network-wide bursts. Moreover, SNCA triplication hMOs exhibit an increase in network synchrony and burst/network burst strength similar to observations in animal and human PD brains. Subsequently, we show that the observed changes in neuronal activity are attributed to dopamine D2 receptor hypoactivity due to dopamine depletion, which could be reversed by the D2 receptor agonist quinpirole. Thus, hMOs faithfully model network wide electrophysiological changes associated with PD progression and serve as a promising tool for PD research and personalized medicine.

Year:

2025

A role of the immune system in Parkinson’s disease (PD) progression has long been suspected due to the increased frequency of activated glial cells and infiltrating T cells into the substantia nigra. It was previously reported that PD donors have increased T cell responses towards PINK1 and α-synuclein (α-syn), two Lewy body-associated proteins. Further, T cell reactivity towards α-syn was highest closer to disease onset, highlighting that autoreactive T cells might play a role in PD pathogenesis. However, whether T cell autoreactivity is present during prodromal PD is unknown. Here, we investigated T cell responses towards PINK1 and α-syn in donors at high risk of developing PD (i.e. prodromal PD: genetic risk, hyposmia, and or REM sleep behavior disorder), in comparison to PD and healthy control donors. T cell reactivity to these two autoantigens was detected in prodromal PD at levels comparable to those detected in individuals with clinically diagnosed PD. Aligned with the increased incidence of PD in males, we found that males with PD, but not females, had elevated T cell reactivity compared to healthy controls. However, among prodromal PD donors, males and females had elevated T cell responses. These differing trends in reactivity highlights the need for further studies of the impact of biological sex on neuroinflammation and PD progression.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (40)

Sali M K Farhan

McGill University

CANADA
View details

Carolyn Marks

Karolinska Institutet

SWEDEN
View details

Avi Rosenberg

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Adriano Aguzzi

-

SWITZERLAND
View details

Alex Wiesman

Assistant Professor

Simon Fraser University

CANADA
View details

Mohamed A. Eldeeb

-

CANADA
View details

Roy Alcalay

Alfred and Minnie Bressler Associate Professor of Neurology

Columbia University Columbia College

UNITED STATES
View details

Thomas M. Durcan

Associate Professor

Montreal Neurological Institute and Hospital

CANADA
View details

Luke Michael Healy

-

CANADA
View details

Yasser Iturria Medina

Associate Professor

Montreal Neurological Institute and Hospital

CANADA
View details

Peter S. McPherson

McGill University

CANADA
View details

D. Louis Collins

Professor

McGill University

CANADA
View details

Carl Laflamme

Assistant Professor

University of Ottawa

CANADA
View details

Opher Gileadi

Head, Protein Sciences

Karolinska Institutet

SWEDEN
View details

Joel Watts

Associate Professor

University of Toronto

CANADA
View details

Emil Johansson

La Jolla Institute for Immunology

UNITED STATES
View details

Sylvain Baillet

Professor

Université de Montréal

CANADA
View details

Ronald B. Postuma

-

CANADA
View details

Bradley Hyman

Professor

Harvard University

UNITED STATES
View details

Jiang-An Yin

Assistant professor

Tsinghua University

CHINA
View details

Cecilia Lindestam Arlehamn

Research Professor

Statens Serum Institut

DENMARK
View details

Natividad Stover

Professor

The University of Alabama

UNITED STATES
View details

David Sulzer

Columbia University

UNITED STATES
View details

Amy Amara

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Jean-François Trempe

Associate Professor

McGill University

CANADA
View details

Marco Antonio Maximo Prado

Scientist, Professor

University of Western Ontario

CANADA
View details

Yihai Cao

Professor at Karolinska Institutet

Karolinska Institutet

SWEDEN
View details

Chanshuai Han

McGill University

CANADA
View details

Elia Duh

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Guy A Rouleau

Professor

McGill University

CANADA
View details

Brian D. Marsden

Associate Professor, Research Informatics

University of Oxford

UNITED KINGDOM
View details

Kalle Gehring

McGill University

CANADA
View details

Irene Litvan

Professor

University of California, San Diego

UNITED STATES
View details

David Standaert

Professor and Chair

The University of Alabama

UNITED STATES
View details

Harvinder Virk

NIHR Academic Clinical Lecturer (Respiratory Medicine)

University of Leicester

UNITED KINGDOM
View details

Mallar Chakravarty

Professor

McGill University

CANADA
View details

Mikko Karttunen

Docent (ENG) / Privat Dozent (GER) / Dosentti (FIN)

Western University

CANADA
View details

Alessandro Sette

Professor and Member

La Jolla Institute for Immunology

UNITED STATES
View details

Susanne Graslund

Karolinska Institutet

SWEDEN
View details

Alain Dagher

Professor

McGill University

CANADA
View details